China's Second-largest CRO Seeks Initial Public Offering In The U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Shanghai-based ShangPharma hopes to capitalize on a growing wave of outsourcing by biopharmaceutical developers looking to reduce costs and spread risk in the wake of an R&D productivity slump.